To cite: Gossec L, Siebert S, Bergmans P, et al. Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study. Annals of the Rheumatic Diseases Published Online First: 13 December 2022. doi: 10.1136/ard-2022-222879
Read the full article here: [ Ссылка ]
Objective: To evaluate real-world persistence and effectiveness of the IL-12/23 inhibitor, ustekinumab or a tumour necrosis factor inhibitor (TNFi) for psoriatic arthritis over 3 years.
Conclusions: At 3 years, there was generally comparable persistence after ustekinumab or TNFi treatment, but AE rates were lower with ustekinumab.
![](https://s2.save4k.ru/pic/ESncqzHlKkk/maxresdefault.jpg)